ALTERITY THERAPEUTICS: 457M NEW OPTIONS TO BE QUOTED ON ASX
Ticker: PRNAF · Form: 6-K · Filed: Jan 18, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: share-dilution, options, capital-structure, regulatory-filing
TL;DR
**Alterity is adding 457 million new options, potentially diluting existing shares.**
AI Summary
Alterity Therapeutics Limited, a pharmaceutical company, announced on January 18, 2024, the application for quotation of 457,142,830 new securities on the ASX. These securities are options expiring on August 31, 2026, with an exercise price of $0.01, issued as a result of options being exercised or convertible securities being converted on January 8, 2024. This matters to investors because the significant increase in potential shares could dilute the value of existing shares if these options are fully exercised, impacting per-share earnings and ownership percentages.
Why It Matters
The potential influx of 457 million new shares could dilute existing shareholder value, impacting share price and ownership stakes if these options are exercised.
Risk Assessment
Risk Level: medium — The large number of new options could lead to significant share dilution, which is a moderate risk for current shareholders.
Analyst Insight
An investor should assess the potential impact of 457 million new shares on the company's market capitalization and per-share metrics. This could signal future dilution, so monitoring the company's capital structure and future financing activities is crucial.
Key Numbers
- 457,142,830 — Number of securities to be quoted (Represents the total number of new options that will be listed on the ASX, potentially increasing the total share count.)
- January 18, 2024 — Date of announcement (The date the 6-K filing was made and the announcement of the application for quotation.)
- August 31, 2026 — Option expiry date (The deadline by which these options can be exercised.)
- $0.01 — Exercise price per option (The cost to convert each option into a share.)
- January 8, 2024 — Issue date of securities (The date the options were issued, prior to the quotation application.)
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant and issuer of securities
- Geoffrey P. Kempler (person) — Chairman of Alterity Therapeutics Limited
- ASX (company) — Australian Securities Exchange where securities will be quoted
- $0.01 (dollar_amount) — Exercise price of the options
Forward-Looking Statements
- The exercise of these 457,142,830 options will lead to significant dilution of existing shares. (Alterity Therapeutics Limited) — high confidence, target: August 31, 2026
- The share price of Alterity Therapeutics Limited may experience downward pressure if a large number of these options are exercised. (Alterity Therapeutics Limited) — medium confidence, target: August 31, 2026
FAQ
What is the purpose of this 6-K filing by Alterity Therapeutics Limited?
This 6-K filing by Alterity Therapeutics Limited is to report the application for quotation of 457,142,830 new securities on the ASX, which are options expiring on August 31, 2026, with an exercise price of $0.01, issued on January 8, 2024.
Who signed this report on behalf of Alterity Therapeutics Limited and when?
The report was signed by Geoffrey P. Kempler, Chairman of Alterity Therapeutics Limited, on January 18, 2024.
What type of securities are being quoted and what is their exercise price and expiry date?
The securities being quoted are options, specifically described as 'OPTION EXPIRING 31-AUG-2026 EX $0.01'. This means they have an exercise price of $0.01 and expire on August 31, 2026.
How many new securities are being applied for quotation?
A total of 457,142,830 new securities are being applied for quotation on the ASX.
Into which existing registration statements will this Form 6-K be incorporated by reference?
This Form 6-K is being incorporated by reference into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-01-18 08:00:17
Filing Documents
- ea191784-6k_alterity.htm (6-K) — 13KB
- ea191784ex99-1_alterity.htm (EX-99.1) — 50KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- ex99-1_002.jpg (GRAPHIC) — 0KB
- 0001213900-24-004290.txt ( ) — 67KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Application for quotation of securities - ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: January 18, 2024 2